Abstract
Rubella remains an important pathogen worldwide, with roughly 100,000 cases of congenital rubella syndrome estimated to occur every year. Rubella-containing vaccine is highly effective and safe and, as a result, endemic rubella transmission has been interrupted in the Americas since 2009. Incomplete rubella vaccination programmes result in continued disease transmission, as evidenced by recent large outbreaks in Japan and elsewhere. In this Seminar, we provide present results regarding rubella control, elimination, and eradication policies, and a brief review of new laboratory diagnostics. Additionally, we provide novel information about rubella-containing vaccine immunogenetics and review the emerging evidence of interindividual variability in humoral and cell-mediated innate and adaptive immune responses to rubella-containing vaccine and their association with haplotypes and single-nucleotide polymorphisms across the human genome.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2297-2307 |
| Number of pages | 11 |
| Journal | The Lancet |
| Volume | 385 |
| Issue number | 9984 |
| DOIs | |
| State | Published - Jun 6 2015 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Rubella. / Lambert, Nathaniel; Strebel, Peter; Orenstein, Walter; Icenogle, Joseph; Poland, Gregory A.
In: The Lancet, Vol. 385, No. 9984, 06.06.2015, p. 2297-2307.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rubella
AU - Lambert, Nathaniel
AU - Strebel, Peter
AU - Orenstein, Walter
AU - Icenogle, Joseph
AU - Poland, Gregory A.
PY - 2015/6/6
Y1 - 2015/6/6
N2 - Rubella remains an important pathogen worldwide, with roughly 100,000 cases of congenital rubella syndrome estimated to occur every year. Rubella-containing vaccine is highly effective and safe and, as a result, endemic rubella transmission has been interrupted in the Americas since 2009. Incomplete rubella vaccination programmes result in continued disease transmission, as evidenced by recent large outbreaks in Japan and elsewhere. In this Seminar, we provide present results regarding rubella control, elimination, and eradication policies, and a brief review of new laboratory diagnostics. Additionally, we provide novel information about rubella-containing vaccine immunogenetics and review the emerging evidence of interindividual variability in humoral and cell-mediated innate and adaptive immune responses to rubella-containing vaccine and their association with haplotypes and single-nucleotide polymorphisms across the human genome.
AB - Rubella remains an important pathogen worldwide, with roughly 100,000 cases of congenital rubella syndrome estimated to occur every year. Rubella-containing vaccine is highly effective and safe and, as a result, endemic rubella transmission has been interrupted in the Americas since 2009. Incomplete rubella vaccination programmes result in continued disease transmission, as evidenced by recent large outbreaks in Japan and elsewhere. In this Seminar, we provide present results regarding rubella control, elimination, and eradication policies, and a brief review of new laboratory diagnostics. Additionally, we provide novel information about rubella-containing vaccine immunogenetics and review the emerging evidence of interindividual variability in humoral and cell-mediated innate and adaptive immune responses to rubella-containing vaccine and their association with haplotypes and single-nucleotide polymorphisms across the human genome.
UR - http://www.scopus.com/inward/record.url?scp=84934296933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934296933&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(14)60539-0
DO - 10.1016/S0140-6736(14)60539-0
M3 - Article
VL - 385
SP - 2297
EP - 2307
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9984
ER -